MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

PRIMARY OBJECTIVES:

I. To assess the clinical utility of images collected by an iPhone application (app)
MoleMapper, and a professional grade portable imaging system (Visiomed microDERM DL200evo
imaging system or 'Visiomed').

II. To incorporate in vivo confocal images into the triage system in order to determine to
what degree the information gathered in this modality changes the classification of a lesion
assigned by a board-certified dermatologist.

OUTLINE:

Participants undergo imaging of suspicious moles via iPhone app MoleMapper, Visiomed, and
confocal microscopy. Participants then receive lidocaine subcutaneously (SC) and undergo
shave or punch biopsy of suspected melanomas.

Inclusion Criteria:

- Persons who participate in the free skin cancer screening at the PDX Skincare Festival
at Oregon Health & Science University (OHSU) on May 19, 2018 and are informed by a
provider that they have a pigmented lesion for which a biopsy is recommended are
potentially eligible to participate in this study.

- Persons who participate in the free skin cancer screening at the War on Skin Cancer
event at OHSU on May 19, 2018 and are informed by a provider that they have a
clinically benign or atypical nevi are eligible to participate in the imaging portion
of this study. No biopsy will be offered to these participants.

- Persons of any race are eligible but we anticipate that most participants will be
Non-Hispanic whites due to the prevalence of melanoma and other skin cancers in this
group.

- Only persons who can provide signed statement of informed consent will be enrolled.

Exclusion Criteria:

- Persons who have not participated in the free skin cancer screening are not eligible
to participate in this study.

- Allergy to the anesthetic (lidocaine).